CN119137131A - 用于调节cot的化合物的固体形式 - Google Patents

用于调节cot的化合物的固体形式 Download PDF

Info

Publication number
CN119137131A
CN119137131A CN202380038374.XA CN202380038374A CN119137131A CN 119137131 A CN119137131 A CN 119137131A CN 202380038374 A CN202380038374 A CN 202380038374A CN 119137131 A CN119137131 A CN 119137131A
Authority
CN
China
Prior art keywords
degrees
formula
theta
solid form
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038374.XA
Other languages
English (en)
Chinese (zh)
Inventor
E·A·卡拉
L·陈
R·D·赛托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN119137131A publication Critical patent/CN119137131A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380038374.XA 2022-05-12 2023-05-10 用于调节cot的化合物的固体形式 Pending CN119137131A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341289P 2022-05-12 2022-05-12
US63/341,289 2022-05-12
PCT/US2023/021659 WO2023220123A1 (en) 2022-05-12 2023-05-10 Solid forms of a compound for modulating cot

Publications (1)

Publication Number Publication Date
CN119137131A true CN119137131A (zh) 2024-12-13

Family

ID=86710687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038374.XA Pending CN119137131A (zh) 2022-05-12 2023-05-10 用于调节cot的化合物的固体形式

Country Status (9)

Country Link
US (1) US20240174702A1 (enExample)
EP (1) EP4522268A1 (enExample)
JP (1) JP2025515671A (enExample)
KR (1) KR20250008904A (enExample)
CN (1) CN119137131A (enExample)
AU (1) AU2023269038A1 (enExample)
CA (1) CA3252705A1 (enExample)
TW (1) TWI863271B (enExample)
WO (1) WO2023220123A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
KR102924836B1 (ko) 2020-03-30 2026-02-09 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
TWI778562B (zh) 2020-04-02 2022-09-21 美商基利科學股份有限公司 製備cot抑制劑化合物的方法
TW202523303A (zh) * 2023-12-11 2025-06-16 美商基利科學股份有限公司 用於治療發炎性腸道疾病之化合物及方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法

Also Published As

Publication number Publication date
AU2023269038A1 (en) 2024-11-28
KR20250008904A (ko) 2025-01-16
WO2023220123A1 (en) 2023-11-16
EP4522268A1 (en) 2025-03-19
TW202400161A (zh) 2024-01-01
TWI863271B (zh) 2024-11-21
CA3252705A1 (en) 2023-11-16
US20240174702A1 (en) 2024-05-30
JP2025515671A (ja) 2025-05-20

Similar Documents

Publication Publication Date Title
US20240174702A1 (en) Solid forms of a compound for modulating cot
EP3962602B1 (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
JP6901479B2 (ja) Ｃｘｃｒ２の阻害剤
US12459908B2 (en) Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
EP3983064B1 (en) Cot modulators and methods of use thereof
US20240010606A1 (en) Fumarate derivatives and their medical use
US10633365B2 (en) Synthesis of indazoles
EP4237402A1 (en) Novel compounds
US20230399289A1 (en) Itaconic acid derivatives
WO2022221642A1 (en) Thienopyrrole compounds
TWI838670B (zh) 經取代之吲哚化合物
US20240360067A1 (en) Derivatives of itaconic acid and their use as anti-inflammatory agents
AU2022219934A9 (en) Thienopyrrole compounds
WO2024127030A1 (en) Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
HK40119474A (zh) 用於调节cot的化合物的固体形式
US12070455B2 (en) Thienopyrrole compounds
US20260138973A1 (en) Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
CN118434720A (zh) 作为丙酮酸激酶调节剂的酞嗪衍生物
EA045296B1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40119474

Country of ref document: HK